ABSTRACT
Glossopharyngeal neuralgia is much less common in children and more difficult to relief its pain symptoms than the adults. We report an experience with peripheral glycerol injection for the control of pain in eight sick children with glossopharyngeal neuralgia. At the latest follow-up, 5 cases had a complete pain-free result after the treatment. There were two sick children who were recurred within three months, of which one child was respond to additional injections. It is concluded that the peripheral glycerol injection is safe and effective in the control of pain symptom among the children with glossopharyngeal neuralgia.
Subject(s)
Glossopharyngeal Nerve Diseases/diagnosis , Glossopharyngeal Nerve Diseases/drug therapy , Glossopharyngeal Nerve/drug effects , Glycerol/administration & dosage , Injections/methods , Nerve Block/methods , Child , Female , Follow-Up Studies , Glossopharyngeal Nerve/pathology , Humans , Injections, Intralymphatic , Male , Pain Measurement , Patient Safety , Recurrence , Retrospective Studies , Risk Assessment , Sampling Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
OBJECTIVE: In order to evaluate the therapeutic value of peripheral glycerol injection (PGI) in children with trigeminal neuralgia (TN). METHODS: A total of 18 sick chlordane with TN have been treated by PGI with a follow-up period ranging from 2.5 to 3.6 years. RESULTS: It is shown that the result is excellent in 72.2%, good in 11.1%, poor in 11.1%, and 22.2% had a recurrence. Of them, 16 of the original patients experienced a satisfactory control of pain following PGI, which produced no changes of the facial sensibility. CONCLUSION: This report indicates that it is a less formidable procedure, simple to perform and easily repeated so remains the choice for the majority of sick children with intractable TN, along with the additional benefit of no risks of facial sensory loss when compared to that of classic neuroectomy.
Subject(s)
Facial Neuralgia/drug therapy , Glycerol/therapeutic use , Trigeminal Nerve/drug effects , Trigeminal Neuralgia/drug therapy , Adolescent , Child , Facial Neuralgia/etiology , Female , Follow-Up Studies , Glycerol/administration & dosage , Humans , Injections/methods , Male , Treatment Outcome , Trigeminal Neuralgia/complicationsABSTRACT
OBJECTIVE: For the present, no definitive treatment is universally accepted for sudden sensorineural hearing loss (SNHL). The goal of this study was to evaluate the role of low-molecular-weight heparins in its therapeutic regimen. METHODS: A retrospective analysis has been taken in 100 patients with SNHL in which they were divided into 2 groups: 50 patients received commonly therapy added with and without low-molecular-weight heparins each. The audiogrametric data at pretreatment were compared with data at day 10 and with data collected at follow-up (average 20 days). RESULTS: The results showed that there was a significant improvement for early or late audiometric outcome in group 1 when compared with group 2 (P <.05). Forty-three patients (86%) were classified into recovery or good improvement in group 1, which was higher than group 2 (P <.01). The improvement rate was calculated for each of the 100 patients, and the average value was 84. Seventy percent in group 1 and 70% in group 2. CONCLUSION: It is concluded that the use of low-molecular-weight heparins not only considerably improve the curative rate in the hearing improvement of sudden sensorineural hearing loss but without such potential risk as unfractionated heparins.
Subject(s)
Anticoagulants/therapeutic use , Hearing Loss, Sudden/drug therapy , Heparin, Low-Molecular-Weight/therapeutic use , Adult , Audiometry/methods , Female , Hearing Loss, Sudden/diagnosis , Humans , Male , Middle Aged , Recovery of Function/drug effects , Retrospective StudiesABSTRACT
OBJECTIVE: By virtue of no identifiable causes in the majority of children with habitual epistaxis, it continues to be problematic in pediatric clinical practice. The purpose of this study is to explore the possible change of atrial natriuretic peptide (ANP) levels in the children with epistaxis. METHODS: Both the plasma and nasal mucus ANP levels have been determined in 30 sick children by a sensitive radioimmunoassay (RIA) technique. RESULTS: Our results revealed that the plasma and nasal mucus ANP levels were considerably decreased in 24 children with habitual epistaxis when compared with control group (P<0.05), making up 80%, and amongst the interest of these are the nasal mucus ANP levels changing inversely as the times bled from the nose. CONCLUSION: Although the plasma and nasal mucus ANP levels will not establish the diagnosis of its etiology, it is helpful for us to know the cardiovascular status compensating for chronic blood loss in the children with habitual epistaxis.
